Nick Naclerio, who founded Motorola’s life science unit and led the launch of CodeLink (later sold to Amersham), joins ParAllele BioScience as president, taking over from former chief Tom Willis. Willis will continue at the company as CSO.
Robin Stears, formerly a senior scientist at Sunnyvale, Calif.’s Telechem/Arrayit, heads to BioRad Laboratories as marketing manager for the microarray business unit.
Lexicon Genetics announces the hiring of William Heydorn as vice president of pre-clinical development. Heydorn has more than 15 years of experience in the field, working at Forest Laboratories, Merrell Dow, and the FDA, among others.
Alex Vodenlich takes on the title of president at GenTel BioSurfaces, a University of Wisconsin, Madison, spinoff from the labs of Robert Corn and Lloyd Smith. Most recently a VP at PanVera, now a unit of Invitrogen, Vodenlich will look to commercialize the company’s biochips.
Texas startup Bacterial BarCodes, based on a molecular identification and DNA fingerprinting technology, hires in David McWilliams as president and CEO. McWilliams has spent 30 years in clinical diagnostics and pharmaceuticals.
As if the trip to Stockholm weren’t enough: Shimadzu announces the establishment of the Koichi Tanaka Mass Spectrometry Research Laboratory. Based in Kyoto, Japan, the lab will be headed by Koichi Tanaka, winner of the 2002 Nobel prize for chemistry, with an aim to improve mass spec technology.
Amersham assigns the new position of chief scientific advisor to James Rothman, who has served on the company’s scientific advisory board for seven years. Rothman is currently chairman of the cellular biochemistry and biophysics program at Memorial Sloan-Kettering Cancer Center.
Cambridge Antibody Technology finds reason to give praise: Richard Mason and Jane Osbourn were both promoted to VP-hood. Mason, who succeeds Jason Avery, will oversee business development. Osbourn becomes VP of display technology, where she will be in charge of parts of the company’s drug discovery work.
Kenneth Olden announces that he will step down from his current posts as director of the National Toxicology Program and the National Institute of Environmental Health Sciences as soon as a replacement is found.
Vincent Miles, formerly at Millennium Pharmaceuticals, becomes senior VP of business development for Alnylam Pharmaceuticals.